These findings clearly suggest low IGF-1 levels to be associated with increased adiposity, inflammation and high comorbidities involving metabolic disorders in obese patients with BMI ≥ 35 kg/cm2, whether they have diabetes or not, independently from other endocrinological axes. Here, IGF1 is linked to metabolic disease.